|
IFIT5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.34620000053532E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.23189999999374E-05 |
| Normal-vs-Stage2 |
3.443800E-01 |
| Normal-vs-Stage3 |
5.79549999999429E-05 |
| Normal-vs-Stage4 |
3.573100E-04 |
| Stage1-vs-Stage2 |
1.259690E-03 |
| Stage1-vs-Stage3 |
3.862600E-01 |
| Stage1-vs-Stage4 |
6.618100E-02 |
| Stage2-vs-Stage3 |
3.562400E-04 |
| Stage2-vs-Stage4 |
1.785010E-04 |
| Stage3-vs-Stage4 |
2.081800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.24699999998401E-07 |
| Normal-vs-AfricanAmerican |
7.978600E-03 |
| Normal-vs-Asian |
2.664200E-02 |
| Caucasian-vs-AfricanAmerican |
1.079240E-01 |
| Caucasian-vs-Asian |
6.293000E-01 |
| AfricanAmerican-vs-Asian |
8.795800E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.673710E-02 |
| Normal-vs-Female |
2.24390000025387E-07 |
| Male-vs-Female |
8.942000E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.74689999996336E-06 |
| Normal-vs-Age(41-60Yrs) |
6.20759999999665E-05 |
| Normal-vs-Age(61-80Yrs) |
4.734400E-02 |
| Normal-vs-Age(81-100Yrs) |
4.174800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.137000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.654810E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.243400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.586600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.550600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.429000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.511500E-02 |
| Classical-VS-Follicular |
<1E-12 |
| Classical-VS-Other |
2.375000E-01 |
| Classical-VS-Normal |
5.1455950611512E-11 |
| Tall-VS-Follicular |
4.55191440096314E-15 |
| Tall-VS-Other |
1.328250E-02 |
| Tall-VS-Normal |
4.22889999684983E-08 |
| Follicular-VS-Other |
5.517800E-02 |
| Follicular-VS-Normal |
1.965530E-04 |
| Other-VS-Normal |
6.246600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.823400E-01 |
| Normal-vs-N1 |
4.228700E-04 |
| N0-vs-N1 |
7.588400E-04 |
|
|
